Skuldtech has been founded in 1999. Since then, several collaborators, scientific consultants, private and capital investors have joined the company.
The company was founded by Didier Ritter and Dr David Piquemal, with the support of Pr Jacques Marti and Pr Therese Commes-Maerten from Montpellier University.
Skuldtech is supported by Oseo, the French SME funding organization, and has been granted a Research Tax Relief ("Agrément Crédit Impôt Recherche") by the French Ministry of Research and Technology.
Since 2004, Skuldtech has received funding from national and international anti-doping agencies (WADA, USADA, AFLD) to identify and validate in a clinical setting the biomarkers associated with erythropoietin (EPO) drug abuse.
In 2006, Skuldtech and Roche Diagnostics have issued an Application Note concerning rapid and accurate gene profiles determined with the "Genome Sequencer System" developed by 454 Life Sciences.
In 2007, Skuldtech has received grants from the European Union for new diagnosis development, the analysis of animal venom as new drug leads (in collaboration with the J. Craig Venter Institute) and for the study of host-pathogenic interactions in the leishmania case.
Moreover, Skuldtech is positioned in the field of “personalized medicine,” which takes people’s biological and physiological differences into account in order to administer the most effective treatments, adapted to match the profile of each patient. Hence, the company takes part in several projects, notably a clinical research program that will make it possible to identify patients with chronic leukemia and high prognostic factors of survival. Skuldtech is also partner of other projects with biotech companies (AB Science...) to develop companion diagnostics that identify patients with positive response to new treatments .
Since october 2012, Skuldtech is the industrial partner of the "Computational Biology Institute" located in Montpellier (France), which "aims at the development of innovative methods and software to analyze, integrate and contextualize large‐scale biological data in the fields of health, agronomy and environment.
Skuldtech is specialized in the discovery of
new Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics
associated with new treatments, especially in
cancer, neurodegenerative and infectious diseases.